RxDoctor Payments Data

Michael Salacz, MD

Medical Oncology · Voorhees, NJNPI 1235178872

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.9% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Medtronic at 29.9% of the total. That places this record below the midpoint for medical oncology clinicians in NJ, where the typical reported total is $1,937.

$597in general payments, 2019–2025

Across 22 payments — averaging $27.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$179
  • Daiichi Sankyo Inc.$126
  • E.r. Squibb & Sons, L.L.C.$71
  • Beone Medicines USA, Inc.$35
  • AbbVie$34
  • Caris MPI, Inc.$29
  • plus $124 from 6 others
$294,981in research payments, 2019–2025

Across 23 payments — averaging $12,825 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$188K
  • Agios Pharmaceuticals, Inc.$68K
  • AbbVie$22K
  • Servier Pharmaceuticals LLC$16K

What the payments were for

  • Food & beverage$54992%
  • Education$488%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$597 in reported general payments places this provider in the 30th percentile of 112 medical oncology providers in New Jersey.

See all medical oncology providers in New Jersey

Medicare billing

Part B allowed, 2024
$15,078
Medicare patients
34
Services billed
145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban14$9,116
Levetiracetam14$380
Ondansetron OdtOndansetron13$262
Dexamethasone11$246
Prednisone37$55

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$9,11614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 112 medical oncology providers in New Jersey.

Other medical oncology in Voorhees

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →